Averting a malaria disaster in Africa: where does the buck stop?

摘要: The serious threat posed by the spread of drug-resistant malaria in Africa has been widely acknowledged. Chloroquine resistance is now almost universal, and to successor drug, sulfadoxine-pyrimethamine (SP), growing rapidly. Combination therapy suggested as being an available potentially lasting solution this impending crisis. However, current cost combination therapy, especially that artemisinin (ACT), a drawback, even if significant part its passed on end-user. If question not successfully addressed could lead adverse results from deployment first-line treatment. These effects range increase fatal delays infected individuals presenting medical services, exclusion poorest sufferers receiving treatment altogether. Urgent steps are needed reduce end-user sustainable way it be usable, some possible approaches discussed.